Kidney Res Clin Pract > Volume 41(1); 2022 > Article |
|
Funding
This study was supported by a Korea University Grant (project no. K2008401). The funders had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript.
Authors’ contributions
Conceptualization, Methodology: MGK
Data curation, Formal analysis: HJM, MGK, JSP, SYP
Funding acquisition: MGK
Investigation: JSY, JHY, SWO, SKJ, WYC, JGG, CWJ, YJS
Writing–original draft: HJM, MGK
Writing–review & editing: JSP, SYP, MGK
All authors read and approved the final manuscript.
Characteristic | Total | Stage I and II | Stage III | Stage IV | p-value |
---|---|---|---|---|---|
Patient | 303 (100) | 160 (52.8) | 89 (29.4) | 54 (17.8) | |
Age (yr) | 43.97 ± 12.28 | 39.04 ± 12.13 | 48.17 ± 10.46 | 51.69 ± 8.50 | <0.001 |
Male sex | 205 (67.7) | 103 (64.4) | 64 (71.9) | 38 (70.4) | 0.28 |
Body mass index (kg/m2) | 23.28 ± 3.75 | 22.44 ± 3.70 | 23.74 ± 3.24 | 25.01 ± 4.02 | <0.001 |
Current smoker | 36 (11.9) | 14 (8.8) | 9 (10.1) | 13 (24.1) | 0.008 |
Causes of ESKD | |||||
Diabetes mellitus | 60 (19.8) | 18 (11.3) | 19 (21.3) | 23 (42.6) | <0.001 |
Hypertension | 75 (24.8) | 30 (18.8) | 31 (34.8) | 14 (25.9) | 0.08 |
Glomerulonephritis | 85 (28.1) | 62 (38.8) | 16 (18.0) | 7 (13.0) | <0.001 |
Polycystic kidney disease | 15 (5.0) | 10 (6.3) | 5 (5.6) | 0 (0) | 0.10 |
Others | 16 (5.3) | 15 (9.4) | 0 (0) | 1 (1.9) | 0.005 |
Unknown | 52 (17.2) | 25 (15.6) | 18 (20.2) | 9 (16.7) | 0.66 |
Renal replacement therapy | |||||
Hemodialysis | 201 (66.3) | 98 (61.3) | 60 (67.4) | 43 (79.6) | 0.02 |
Peritoneal dialysis | 49 (16.2) | 27 (16.9) | 17 (19.1) | 5 (9.3) | 0.32 |
Preemptive | 53 (17.5) | 35 (21.9) | 12 (13.5) | 6 (11.1) | 0.04 |
Dialysis vintage (mo) | 14.94 ± 25.80 | 14.19 ± 22.87 | 17.09 ± 30.33 | 13.53 ± 26.02 | 0.67 |
Comorbidity | |||||
Hypertension | 272 (89.8) | 143 (89.4) | 83 (93.3) | 46 (85.2) | 0.20 |
Diabetes mellitus | 73 (24.1) | 22 (13.8) | 25 (28.1) | 26 (48.1) | <0.001 |
Dyslipidemia | 185 (61.1) | 93 (58.1) | 54 (60.7) | 38 (70.4) | 0.14 |
Ejection fraction of heart | 57.26 ± 7.19 | 58.32 ± 6.77 | 56.35 ± 6.76 | 55.54 ± 8.67 | 0.02 |
Laboratory test | |||||
Hemoglobin (g/dL) | 10.43 ± 1.68 | 10.44 ± 1.63 | 10.50 ± 1.88 | 10.29 ± 1.51 | 0.76 |
Albumin (g/dL) | 3.95 ± 0.49 | 4.00 ± 0.48 | 3.90 ± 0.51 | 3.90 ± 0.48 | 0.23 |
CRP (mg/L), 10 × hsCRPa | 4.88 ± 15.41 | 2.80 ± 5.79 | 5.74 ± 15.07 | 9.68 ± 28.93 | 0.01 |
LDL (mg/dL) | 85.13 ± 30.47 | 84.70 ± 32.57 | 83.13 ± 28.67 | 89.62 ± 26.88 | 0.46 |
Triglyceride (mg/dL) | 125.95 ± 85.88 | 124.59 ± 78.57 | 125.51 ± 90.30 | 130.62 ± 99.28 | 0.91 |
Calcium (mg/dL) ×phosphate (mg/dL) | 47.96 ± 16.42 | 47.24 ± 16.45 | 49.57 ± 16.44 | 47.42 ± 16.42 | 0.55 |
iPTH (pg/mL) | 250.66 ± 246.75 | 256.21 ± 284.45 | 243.97 ± 208.09 | 245.48 ± 182.61 | 0.92 |
Donor age (yr) | 45.86 ± 10.92 | 46.21 ± 10.50 | 45.99 ± 11.37 | 44.63 ± 11.52 | 0.65 |
Data are expressed as number (%) or mean ± standard deviation.
CRP, C-reactive protein; ESKD, end-stage kidney disease; hsCRP, high sensitivity CRP; iPTH, intact parathyroid hormone; LDL, low-density lipoprotein.
ahsCRP of Seoul National University Hospital converted to CRP of Korea University Medical Center with s conversion factor (10) by method of Milone et al. [9].
Variable | Total | Stage I and II | Stage III | Stage IV | p-value |
---|---|---|---|---|---|
No. of HLA mismatch | 3.39 ± 1.57 | 3.19 ± 1.61 | 3.61 ± 1.60 | 3.63 ± 1.32 | 0.06 |
Induction immunosuppressive agent | |||||
Simulecta | 263 (86.8) | 143 (89.4) | 76 (85.4) | 44 (81.5) | 0.12 |
Maintenance immunosuppressive agent (initial) | |||||
Tacrolimus-based regimenb | 285 (94.1) | 150 (93.8) | 82 (92.1) | 53 (98.1) | 0.26 |
Maintenance immunosuppressive agent (at 1 yr) | |||||
Tacrolimus-based regimen | 249 (91.5) | 131 (92.3) | 71 (88.7) | 47 (94.0) | 0.95 |
Tacrolimus + mycophenolate | 207 (76.1) | 105 (73.9) | 60 (75.0) | 42 (84.0) | 0.20 |
Tacrolimus + sirolimus | 27 (9.9) | 16 (11.3) | 9 (11.3) | 2 (4.0) | 0.20 |
Tacrolimus + bredinin | 15 (5.5) | 10 (7.0) | 2 (2.5) | 3 (6.0) | 0.51 |
Cyclosporine + mycophenolate | 23 (8.5) | 11 (7.7) | 9 (11.3) | 3 (6.0) | 0.95 |
Variable | Total (n = 303) | Stage I and II (n = 160) | Stage III (n = 89) | Stage IV (n = 54) | p-value |
---|---|---|---|---|---|
GFR (mL/min/1.73 m2) | |||||
1-Month GFR | 69.82 ± 19.91 | 69.71 ± 20.50 | 70.12 ± 17.73 | 69.62 ± 21.83 | 0.99 |
1-Year GFRa | 65.67 ± 16.96 | 64.68 ± 18.50 | 67.19 ± 12.61 | 66.43 ± 18.03 | 0.56 |
3-Year GFRb | 67.31 ± 17.71 | 67.07 ± 19.76 | 67.96 ± 13.41 | 67.14 ± 14.55 | 0.95 |
Rejection | |||||
AMR | 18 (5.9) | 9 (5.6) | 4 (4.5) | 5 (9.3) | 0.47 |
ATMR or borderline ATMR | 113 (37.3) | 69 (43.1) | 31 (34.8) | 13 (24.1) | 0.01 |
Graft loss | 14 (4.6) | 7 (4.4) | 4 (4.5) | 3 (5.6) | 0.75 |
Infection | |||||
Bacterial infection | 71 (23.4) | 39 (24.4) | 19 (21.3) | 13 (24.1) | 0.84 |
CMV viremia | 43 (14.2) | 20 (12.5) | 17 (19.1) | 6 (11.1) | 0.82 |
BK viremia | 53 (17.5) | 33 (20.6) | 15 (16.9) | 5 (9.3) | 0.06 |
ATG, anti-thymocyte globulin; CI, confidence interval; CMV, cytomegalovirus; CRP, C-reactive protein; CsA, cyclosporine; HbA1c, hemoglobin A1c; IS, immunosuppressant; KT, kidney transplantation; OR, odds ratio.
In the age, sex-adjusted model, an enter selection approach was adopted. In the multivariate logistic analysis model, age, male sex, donor age, CRP, number of human leukocyte antigen mismatch, relationship, year of KT, induction immunosuppressive agent, maintenance immunosuppressive agent at 1 year, stage of periodontitis were adjusted. Multivariate logistic regression was performed with variables with p-value less than 0.3 in univariate analysis; a backward stepwise selection approach was adopted. All laboratory data were examined prior to KT.
Variable | Total (n = 202) | Stage I and II (n = 127) | Stage III (n = 52) | Stage IV (n = 23) | p-value |
---|---|---|---|---|---|
Cardiovascular disease | 9 (4.5) | 3 (2.4) | 2 (3.8) | 4 (17.4) | 0.006 |
Coronary artery diseasea | 8 (4.0) | 3 (2.4) | 2 (3.8) | 3 (13.0) | 0.03 |
Cerebrovascular disease | 1 (0.5) | 0 (0) | 0 (0) | 1 (4.3) | 0.03 |
CI, confidence interval; ESKD, end-stage kidney disease; iPTH, intact parathyroid hormone; KT, kidney transplantation; OR, odds ratio.
In the multivariate logistic analysis model, age, male sex, donor age, hemoglobin A1c, iPTH, cause of end-stage renal disease (diabetes mellitus, glomerulonephritis), year of KT, stage of periodontitis were adjusted. Multivariate logistic regression was performed with variables with p-value less than 0.3 in univariate analysis; a backward stepwise selection approach was adopted. All laboratory data were examined prior to KT. Dyslipidemia was defined as those with low-density lipoprotein cholesterol greater than 100 mg/dL or triglyceride greater than 500 mg/dL or under lipid-lowering agent.
Hyeon-Jin Min
https://orcid.org/0000-0003-4377-4172
Jung-Soo Park
https://orcid.org/0000-0003-0653-2422
Jaeseok Yang
https://orcid.org/0000-0002-1119-0407
Jihyun Yang
https://orcid.org/0000-0002-8616-238X
Se Won Oh
https://orcid.org/0000-0003-3795-9322
Sang-Kyung Jo
https://orcid.org/0000-0002-0496-0258
Won Yong Cho
https://orcid.org/0000-0001-8627-8940
Jun Gyo Gwon
https://orcid.org/0000-0002-1681-1014
Cheol Woong Jung
https://orcid.org/0000-0002-0776-8202
Yang-Jo Seol
https://orcid.org/0000-0002-2076-5452
Shin-Young Park
https://orcid.org/0000-0002-3776-4130
Myung-Gyu Kim
https://orcid.org/0000-0001-8807-2452
Necessity of induction agent modification for old age kidney transplant recipients